Business
WuXi XDC Continues to Deliver Robust Business Growth and Financial Results in 1H 2025, Strengthening Global CRDMO Leadership Position in Bioconjugates Industry
WuXi XDC Cayman Inc. (the "WuXi XDC" or the "Group", stock code: 2268.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) focused on the bioconjugate market, is pleased to announce its interim results for the first half of 2025 (the "Reporting Period").
About this update from Wuxi Xdc Cayman, Inc.
[{"type":"text","content":"- Revenue increased by 62.2% YoY to RMB 2,701 million - Gross profit surged by 82.2% YoY to RMB 975 million, with its margin of 36.1%- Adjusted net profit before interest income and expense increased by 69.6% YoY to RMB 733 million, with its margin of 27.1%- Adjusted net profit including interest income and expense increased by 50.1% YoY to RMB 801 million, with its margin of 29.6%- Net profit grew by 52.7% YoY to RMB 746 million, with its margin of 27.6%- The total global customer base expanded to 563, adding 64 new customers in 1H 2025 - The total number of iCMC projects reached 225, with 37 newly signed iCMC projects in 1H 2025- The total backlog grew to US$1,329 million, representing a 57.9% YoY growth- DP3 facility at the Wuxi site achieved GMP release, further enhanced All-in-One manufacturing capability - Singapore site achieved mechanical completion of site construction and will achieve GMP release in 1H 2026 - Continue to invest in frontier technology and empower clients to explore and unlock frontier modalities, solidifying the Group's competitiveness and leadership position- Multiple Top Awards from "2025 Asia (ex-Japan) Best Executive Team" by Extel (previously "Institutional Investor")- Bilingual conference calls are scheduled on August 19, 2025, at 8:30 a.m. and 8:30 p.m. HKT, respectively","length":1420,"tagName":"p","attribs":{}},{"type":"text","content":"SHANGHAI, Aug. 18, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. (the "WuXi XDC" or the "Group", stock code: 2268.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) focused on the bioconjugate market, is pleased to announce its interim results for the first half of 2025 (the "Reporting Period").","length":364,"tagName":"p"},{"type":"text","content":"Dr. Jimmy Li, CEO of WuXi XDC, stated, "In the first half of 2025, WuXi XDC has once again exemplified the robustness of our integrated CRDMO model and the agility of our global teams. Amid a rapidly advancing bioconjugate landscape, we delivered record growth in project signing, expanded our customer base, and advanced our technology platforms and capacity expansion milestones. These achievements underscore our unwavering commitment to innovation, quality, and c...